Bristol-myers Squibb Compnay

Engmab Ag

Engmab Sarl

Engmab Beta Holdings LLC

Sabine Jung-Imhof

Christian Klein

Ekkehard Moessner

Pablo Umana

Wolfgang Schaefer

Joerg Thomas Regula

Ralf Hosse

Michael Molhoj

Anne Freimoser-Grundschober

Stefan Klostermann

Oliver Ast

Tanja Fauti

Klaus Strein

Samuel Moser

Minh Diem Vu

Ramona Murr

Marina Bacac

Lydia Jasmin Hanisch

Anne Freimoser-grundschober

The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.

Bispecific antibodies against CD3EPSILON and ROR1

A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3&#x3b5;, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.

Bispecific antibodies against CD3&#x3f5; and BCMA

Growing community of inventors

Planegg, Germany

Sabine Jung-Imhof